## BEST AVAILABLE COPY

MAR. 6. 2006 11:49AM AVENTIS US PAT DEPT TO: US CENTRALIZED USPTO

# RECEIVED P. 1/21 CENTRAL FAX CENTER

MAR 0 6 2006

| TRANSMITTA FORM  (10 be used for all correspondence on Total Number of Pages in This Submiss   | AL<br>or initial filing)                | Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number  | Januar<br>Mantre<br>1626<br>A. Pavi | ,600<br>y 05, 2004<br>d SCHUDO   | DK et al.   |
|--|---|--|-------------------------------------|--|---|
| ENCLOSURES (Check all that apply)  |   |  |                                     |  |   |
| Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affigavits/declaration(s  Extension of Time Request  Express Abandonment Request  Information Disclopure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ incomplete Application  Reply to Missing Parts/ under S7 CFR 1.52 or 1 | D L L P P P P P P P P P P P P P P P P P | Drawing(s)  icensing-related Papers  Prition  Prition to Convert to a provisional Application tower of Attorney, Revocal thange of Correspondence erminal Disclaimer equest for Refund  D. Number of CD(s)  Landscape Table on C | Von<br>: Address                    | And Application of the Applicati | peal Communication to Board Appeals and Interferences peal Communication to TC poal Notice, Brief, Reply Brief) sprietary Information turns Letter per Enclosure(s) (please Identify ow): |
| SIG  | NATURE OF                               | APPLICANT, ATTO  | PNEY OF                             | ACENT  |   |
| AVENTIS PHARM  |   |  | TAILET, OF                          | KAGENT   |   |
| Signature Printed name Joseph D. Ribssi  | 0.1                                     | usei   |                                     |  |   |
| Date March 6, 2006   |   |  | Reg. No.                            | 47,038   |   |
| I hereby certify that this correspondence sufficient postage as first class mail in at this date shown below: (USPTO FAX NO Signature  | is being facsimite                      | TE OF TRANSMISS be transmitted to the USPY seed to: Commissioner for Total No, of Pag  | ON/MAILI                            | NG<br>d with the U   | nited States Postal Service with<br>Alexandria, VA 22313-1450 on  |
| Typed or printed name Paul Irvino  | 29                                      | <u> </u>   |                                     | Date   | March 6, 2006   |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary lepending upon the individual case. Any comments on the meant of the you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patern and ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS

#### **DEAV2003/0001 US NP**

## PATENT CENTRAL FAX CENTER

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 0 6 2006

In re Application of SCHUDOK, et al.

Examiner:

A. Paviglianiti

Art Unit:

1626

Application No.: 10/751,600

January 5, 2004

Title:

Filed:

IMINO ACID DERIVATIVES AS

INHUBITORS OF MATRIX **METALLOPROTEINASES**  TELEFAX CERTIFICATE
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313-1450, on

March 6, 2006

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

#### REPLY TO FINAL ACTION PURSUANT TO 37 CFR § 1.116

This paper is a Reply to the Final Action dated January 26, 2006 ("the Action") pursuant to 37 C.F.R. § 1.116 in connection with the above-identified patent application. Applicants respectfully request that the application be amended, without prejudice, as follows:

- 冈 Amendments to the claims are reflected in the Listing of Claims, which begins on page 2 of this paper.
- $\boxtimes$ Remarks/Arguments begin on page 19 of this paper.